Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-β1

Vaccine

Volumn 26, Issue 41, 2008, Pages 5269-5275

  Fletcher, Helen A ^a   Pathan, Ansar A ^a   Berthoud, Tamara K ^a   Dunachie, Susanna J ^a   Whelan, Kathryn T ^a   Alder, Nicola C ^b   Sander, Clare R ^a   Hill, Adrian V S ^a   McShane, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Regulatory T cells; TGF 1; Tuberculosis

Indexed keywords

BCG VACCINE; CD4 ANTIGEN; CYTOKINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2 RECEPTOR ALPHA; MESSENGER RNA; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM TUBERCULOSIS ANTIGEN 85A; RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA VACCINE; RECOMBINANT VACCINE; STREPTODORNASE; STREPTOKINASE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIGEN EXPRESSION; ARTICLE; BCG VACCINATION; CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOREGULATION; NONHUMAN; NORMAL HUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

ACYLTRANSFERASES; ADOLESCENT; ADULT; ANTIGENS, BACTERIAL; BCG VACCINE; DOWN-REGULATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TRANSFORMING GROWTH FACTOR BETA1; TUBERCULOSIS VACCINES;

EID: 50849089275     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.040     Document Type: Article

References (38)

1. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271 9 (1994) 698-702
2. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 5514 (2001) 69-74
3. Bejon P., Mwacharo J., Kai O.K., Todryk S., Keating S., Lang T., et al. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Vaccine 24 22 (2006) 4709-4715
4. Goonetilleke N., Moore S., Dally L., Winstone N., Cebere I., Mahmoud A., et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 80 10 (2006) 4717-4728
5. Hutchings C.L., Gilbert S.C., Hill A.V., and Moore A.C. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol 175 1 (2005) 599-606
6. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9 6 (2003) 729-735
7. Moorthy V.S., Imoukhuede E.B., Milligan P., Bojang K., Keating S., Kaye P., et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 1 2 (2004) e33
8. Smith C.L., Dunbar P.R., Mirza F., Palmowski M.J., Shepherd D., Gilbert S.C., et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 113 2 (2005) 259-266
9. Goonetilleke N.P., McShane H., Hannan C.M., Anderson R.J., Brookes R.H., and Hill A.V. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171 3 (2003) 1602-1609
10. McShane H., Brookes R., Gilbert S.C., and Hill A.V. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 69 2 (2001) 681-686
11. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10 11 (2004) 1240-1244
12. Pathan A.A., Sander C.R., Fletcher H.A., Poulton I., Alder N.C., Beveridge N.E., et al. Boosting BCG with recombinant modified vaccinia Ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS One 2 10 (2007) e1052
13. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198 12 (2003) 1875-1886
14. Fontenot J.D., Gavin M.A., and Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4 4 (2003) 330-336
15. Lucas P.J., Kim S.J., Melby S.J., and Gress R.E. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor. J Exp Med 191 7 (2000) 1187-1196
16. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359 6397 (1992) 693-699
17. Fantini M.C., Becker C., Monteleone G., Pallone F., Galle P.R., and Neurath M.F. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172 9 (2004) 5149-5153
18. Marie J.C., Letterio J.J., Gavin M., and Rudensky A.Y. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 201 7 (2005) 1061-1067
19. Walther M., Tongren J.E., Andrews L., Korbel D., King E., Fletcher H., et al. Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity 23 3 (2005) 287-296
20. Roncador G., Brown P.J., Maestre L., Hue S., Martinez-Torrecuadrada J.L., Ling K.L., et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 35 6 (2005) 1681-1691
21. Dunachie S.J., Walther M., Epstein J.E., Keating S., Berthoud T., Andrews L., et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 74 10 (2006) 5933-5942
22. Mwau M., Cebere I., Sutton J., Chikoti P., Winstone N., Wee E.G., et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85 Pt 4 (2004) 911-919
23. Webster D.P., Dunachie S., McConkey S., Poulton I., Moore A.C., Walther M., et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24 15 (2006) 3026-3034
24. Wang J., Ioan-Facsinay A., van der Voort E.I., Huizinga T.W., and Toes R.E. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 37 1 (2007) 129-138
25. Moore A.C., Gallimore A., Draper S.J., Watkins K.R., Gilbert S.C., and Hill A.V. Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance. J Immunol 175 11 (2005) 7264-7273
26. Toka F.N., Suvas S., and Rouse B.T. CD4+ CD25+ T cells regulate vaccine-generated primary and memory CD8+ T-cell responses against herpes simplex virus type 1. J Virol 78 23 (2004) 13082-13089
27. Classen S., Zander T., Eggle D., Chemnitz J.M., Brors B., Buchmann I., et al. Human resting CD4+ T cells are constitutively inhibited by TGF beta under steady-state conditions. J Immunol 178 11 (2007) 6931-6940
28. Grainger D.J., Heathcote K., Chiano M., Snieder H., Kemp P.R., Metcalfe J.C., et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 8 1 (1999) 93-97
29. Ulloa L., Doody J., and Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 397 6721 (1999) 710-713
30. Hirsch C.S., Hussain R., Toossi Z., Dawood G., Shahid F., and Ellner J.J. Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production. Proc Natl Acad Sci USA 93 8 (1996) 3193-3198
31. Hirsch C.S., Toossi Z., Othieno C., Johnson J.L., Schwander S.K., Robertson S., et al. Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J Infect Dis 180 6 (1999) 2069-2073
32. Othieno C., Hirsch C.S., Hamilton B.D., Wilkinson K., Ellner J.J., and Toossi Z. Interaction of Mycobacterium tuberculosis-induced transforming growth factor beta1 and interleukin-10. Infect Immun 67 11 (1999) 5730-5735
33. Roberts T., Beyers N., Aguirre A., and Walzl G. Immunosuppression during active tuberculosis is characterized by decreased interferon-gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor-beta, and interleukin-4 mRNA levels. J Infect Dis 195 6 (2007) 870-878
34. Hernandez-Pando R., Orozco-Esteves H., Maldonado H.A., Aguilar-Leon D., Vilchis-Landeros M.M., Mata-Espinosa D.A., et al. A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis. Clin Exp Immunol 144 2 (2006) 264-272
35. Guyot-Revol V., Innes J.A., Hackforth S., Hinks T., Lalvani A., and Regulatory. T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med 173 7 (2006) 803-810
36. Ribeiro-Rodrigues R., Resende Co T., Rojas R., Toossi Z., Dietze R., Boom W.H., et al. A role for CD4+CD25+ T cells in regulation of the immune response during human tuberculosis. Clin Exp Immunol 144 1 (2006) 25-34
37. Scott-Browne J.P., Shafiani S., Tucker-Heard G., Ishida-Tsubota K., Fontenot J.D., Rudensky A.Y., et al. Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J Exp Med 204 9 (2007) 2159-2169
38. Kempf K., Haltern G., et al. Increased TNF-alpha and decreased TGF-beta expression in peripheral blood leukocytes after acute myocardial infarction. Horm Metab Res 38 5 (2006) 346-351